Boehringer Ingelheim, a global leader in biopharmaceuticals, has partnered with Mission for Essential Drugs and Supplies (MEDS) to expand its ‘Access to Healthcare’ program in Kenya.
The collaboration seeks to enhance access to affordable medications for patients with type 2 diabetes and hypertension, while strengthening local healthcare capacity.
Launched in 2022, the program has already engaged 200 physicians, enrolled 1,500 patients, and partnered with 15 healthcare facilities.
MEDS and Boehringer Ingelheim aims to deepen its impact and reach more underserved communities across Kenya. The initiative also includes awareness campaigns to educate the public about these non-communicable diseases, promoting early diagnosis and treatment.
Derek O’Leary, Regional Managing Director at Boehringer Ingelheim, stated, “This partnership with MEDS is a testament to our shared vision of making quality healthcare accessible to all. We are committed to delivering hope and transforming lives through innovative solutions and collaboration.”
Hale Asikogllu-Erkol, Head of Sustainable Development for Generations, added, “Our Sustainable Development for Generations framework is about creating long-term value and improving lives. This partnership with MEDS is a step toward achieving our goal of expanding healthcare access for 50 million people globally by 2030.”
Dr. Stephen Kigera of MEDS noted, “We are excited to work with Boehringer Ingelheim to provide cutting-edge treatments and improve health outcomes for patients in Kenya. Together, we aim to build a healthier future for generations to come.”
This partnership underscores Boehringer Ingelheim’s dedication to addressing NCDs and advancing global health equity, ensuring that no one is left behind in accessing essential healthcare.
